Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Core Insights - The company is focused on the successful launch of FILSPARI in IgA nephropathy as its top priority for the year [1] - There have been positive performance results in the first half of the year, with plans for exciting updates in the latter half [1] - The company has modified the liver monitoring REMS and removed the pregnancy testing REMS to simplify patient access [1] - The second priority involves ongoing work with the FDA for potential approval in FSGS [2]